Pneumagen Showcases Neumifil's Phase 2 Results at ATS 2024

St Andrews-based biotech firm Pneumagen, which is in the clinical stage of development, is set to present findings from a human challenge study involving its antiviral drug Neumifil at the 2024 American Thoracic Society (ATS) Conference. The study, conducted in San Diego, will showcase Neumifil's potential in managing respiratory tract infections (RTIs) and its capacity to mitigate viral-induced exacerbations in individuals with Chronic Obstructive Pulmonary Disease (COPD). The drug, an innovative intranasal medication, is designed to offer broad-spectrum protection and treatment against a range of viral pathogens.

The clinical data will be unveiled through oral and ePoster sessions, with the oral presentation titled "HEX17, A Novel Broad-spectrum Antiviral Intranasal Drug, Demonstrates Efficacy Against Influenza in a Controlled Human Infection Model Conducted in Healthy Adults." The session will take place on Tuesday, May 21, from 9:15 AM to 11:15 AM EST, at the San Diego Convention Centre, Room 6C-F. Geoff Kitson, Pneumagen's Chief Medical Officer, will be the presenter.

The ePoster, sharing the same title as the oral presentation, will be available online from Tuesday, May 21, to Friday, September 6, as part of the Translating Science in Respiratory Infections session. The authors of the study include Geoff Kitson and his colleagues.

Neumifil is a groundbreaking product in Pneumagen's portfolio, engineered using a multivalent Carbohydrate Binding Module (mCBM). It functions by binding to viral pathogens and preventing their entry into the host. The development of Neumifil was facilitated by Pneumagen's proprietary GlycoTarge™ technology, which is also being used to advance a pipeline of therapies for other infectious diseases.

Founded in 2016 as a spin-off from the University of St Andrews in Scotland, Pneumagen benefits from access to top-tier scientific knowledge and expertise in the field of viral infections, particularly in relation to glycobiology. The company's mission is to leverage this expertise to develop innovative treatments for a wide array of infectious diseases.